Physician

Mark Jon Pamer, D.O.

According to 2025 Medicare claims, Mark Pamer, D.O. (NPI: 1184824542) practices pulmonary disease in the Port St. Lucie, FL market, with the plurality of this provider's patient population coming from St. Lucie, FL. This provider's primary affiliated billing organization is MARK J. PAMER, D.O., L.L.C. (NPI: 1679716690; TIN: 264193963) and primary practice location at 34986-1825.

Pamer's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,017 traditional Medicare patients, billed 45,060 HCPCS/CPT codes, and received $1,309,938 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 6,549 prescription claims across 995 beneficiaries totaling $4,410,769 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 6,498 claims. Open Payments data shows 168 records totaling $23,471. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $265,284 to $1,309,938. Similarly, Part D prescription costs have risen steadily, from $1,233,039 to $4,410,769. For DME billing, reported payments rose steadily, from $226,532 to $399,615.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	589	4,416	$265,284
2016	763	6,289	$340,249
2017	756	9,447	$383,611
2018	803	11,258	$458,968
2019	943	17,997	$685,848
2020	948	27,570	$728,925
2021	1,254	69,842	$1,310,737
2022	1,086	52,827	$1,300,981
2023	1,056	51,922	$1,370,022
2024	1,017	45,060	$1,309,938

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	396	4,657	$1,233,039
2016	505	5,889	$1,698,224
2017	599	6,600	$1,776,988
2018	715	6,762	$2,217,767
2019	737	6,390	$2,569,548
2020	662	4,924	$2,716,663
2021	634	4,374	$2,981,919
2022	652	3,982	$2,914,035
2023	788	4,789	$3,708,312
2024	995	6,549	$4,410,769

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	944	4,951	$719,205
2016	1,168	5,505	$823,978
2017	1,344	6,007	$959,694
2018	1,354	6,093	$1,330,882
2019	1,705	7,354	$1,881,944
2020	1,577	7,079	$2,184,218
2021	1,283	5,827	$1,946,286
2022	1,182	5,327	$1,570,509
2023	1,611	6,688	$1,840,387
2024	1,667	6,498	$1,422,923

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	798	1,380	$87
94729	Test to examine how well the lungs exchange gases	465	486	$41
94726	Test to determine lung volumes using sensors	463	484	$40
99457	Management using the results of remote vital sign monitoring per calendar month, first 20 minutes	317	1,362	$37
94060	Test to measure expiratory airflow and volume changes before and after medication administration	459	480	$27

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	789	38,484	$795,681
Ofev	Nintedanib Esylate	52	1,860	$754,456
Opsumit	Macitentan	43	1,290	$541,468
Prolastin C	Alpha-1-Proteinase Inhibitor	16	448	$250,664
Breo Ellipta	Fluticasone/Vilanterol	312	14,070	$180,052

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin	N	N/R	73	$379,099
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	69	441	$338,015
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	19	143	$144,505
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each	Y	12	84	$77,488
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	N	N/R	24	$75,734

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	168	$23,471	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark Jon Pamer, D.O.?

Tedicare shows public-source Medicare data for Mark Jon Pamer, D.O. (NPI 1184824542), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Jon Pamer, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark Jon Pamer, D.O.?

Mark Jon Pamer, D.O. is linked to MARK J. PAMER, D.O., L.L.C. (billing NPI 1679716690) in the available physician profile data.

Does Mark Jon Pamer, D.O. have Open Payments data?

Mark Jon Pamer, D.O. has 168 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.